Analyst Ratings For Seattle Genetics (NASDAQ:SGEN)
Today, Morgan Stanley lowered its price target on Seattle Genetics (NASDAQ:SGEN) to $67.00 per share.
Some recent analyst ratings include
- 3/20/2018-Royal Bank of Canada Reiterated Rating of Buy.
- 3/20/2018-Cann Reiterated Rating of Hold.
- 3/20/2018-Barclays initiated coverage with a Overweight rating.
- 3/13/2018-Cowen Reiterated Rating of Hold.
- 2/14/2018-JPMorgan Chase & Co. Upgrade from a “Neutral ” rating to a ” Overweight” rating.
Recent Insider Trading Activity For Seattle Genetics (NASDAQ:SGEN)
Seattle Genetics (NASDAQ:SGEN) has insider ownership of 34.70% and institutional ownership of 93.09%.
- On 3/15/2018 Vaughn B. Himes, Insider, sold 5,000 with an average share price of $58.12 per share and the total transaction amounting to $290,600.00.
- On 3/9/2018 Clay B. Siegall, CEO, sold 18,832 with an average share price of $57.32 per share and the total transaction amounting to $1,079,450.24.
- On 3/5/2018 Jonathan G. Drachman, CMO, sold 10,457 with an average share price of $52.83 per share and the total transaction amounting to $552,443.31.
- On 2/9/2018 Clay B. Siegall, Insider, sold 18,832 with an average share price of $49.75 per share and the total transaction amounting to $936,892.00.
- On 2/1/2018 Bros. Advisors Lp Baker, Director, bought 3,846,153 with an average share price of $52.00 per share and the total transaction amounting to $199,999,956.00.
- On 1/11/2018 Clay B. Siegall, Insider, sold 18,832 with an average share price of $51.71 per share and the total transaction amounting to $973,802.72.
- On 12/11/2017 Clay B. Siegall, Insider, sold 18,832 with an average share price of $55.40 per share and the total transaction amounting to $1,043,292.80.
Recent Trading Activity for Seattle Genetics (NASDAQ:SGEN)
Shares of Seattle Genetics closed the previous trading session at 54.67 down -0.19 0.35% with 54.790000915527344 shares trading hands.